• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma.

作者信息

Agrawal Swastik

机构信息

Department of Gastroenterology, Maharishi Markandeshwar Institute of Medical Science and Research, Maharishi Markandeshwar University, Mullana, Ambala, India.

出版信息

J Clin Exp Hepatol. 2016 Dec;6(4):339-342. doi: 10.1016/j.jceh.2016.11.001. Epub 2016 Dec 15.

DOI:10.1016/j.jceh.2016.11.001
PMID:28003728
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5157915/
Abstract
摘要

相似文献

1
Looking Beyond Sorafenib to Treat Advanced Hepatocellular Carcinoma.超越索拉非尼治疗晚期肝细胞癌
J Clin Exp Hepatol. 2016 Dec;6(4):339-342. doi: 10.1016/j.jceh.2016.11.001. Epub 2016 Dec 15.
2
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较（SARAH）：一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
3
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
4
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.索拉非尼联合低剂量顺铂和氟尿嘧啶肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌的随机、开放标签、3 期试验（SILIUS）
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.
5
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.索拉非尼耐药的晚期肝细胞癌患者中 S-1 与安慰剂的比较（S-CUBE）：一项随机、双盲、多中心、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):407-417. doi: 10.1016/S2468-1253(17)30072-9. Epub 2017 Apr 6.
6
Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma.索拉非尼治疗转移性肝细胞癌患者首次进展后的疗效。
Hepatol Res. 2014 Mar;44(3):296-301. doi: 10.1111/hepr.12123. Epub 2013 Apr 29.
7
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.索拉非尼与立体定向体部放疗治疗不可切除的晚期肝细胞癌的成本效益
Radiat Oncol. 2016 May 18;11:69. doi: 10.1186/s13014-016-0644-4.
8
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.瑞戈非尼治疗后索拉非尼治疗失败的晚期肝细胞癌患者的 Ramucirumab（REACH-2）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet Oncol. 2019 Feb;20(2):282-296. doi: 10.1016/S1470-2045(18)30937-9. Epub 2019 Jan 18.
9
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.接受索拉非尼治疗的晚期肝细胞癌患者健康相关生活质量的纵向变化及其对临床病程的影响。
BMC Cancer. 2016 Nov 11;16(1):878. doi: 10.1186/s12885-016-2908-7.
10
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.替吉奥单抗联合索拉非尼作为晚期肝细胞癌一线治疗的安全性和有效性：一项 2 期随机研究。
J Hepatol. 2015 Oct;63(4):896-904. doi: 10.1016/j.jhep.2015.06.001. Epub 2015 Jun 10.

引用本文的文献

1
methanolic extract triggers apoptosis in HepG2 cells.甲醇提取物可引发肝癌细胞（HepG2细胞）凋亡。
Avicenna J Phytomed. 2018 Nov-Dec;8(6):504-512.

本文引用的文献

1
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.肝切除术治疗伴有门静脉侵犯的肝细胞癌的生存获益。
J Hepatol. 2016 Nov;65(5):938-943. doi: 10.1016/j.jhep.2016.05.044. Epub 2016 Jun 4.
2
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.雷莫芦单抗联合索拉非尼二线治疗晚期肝细胞癌 - SHELTER 研究。
J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4.
3
Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion.肝切除术是治疗涉及单个大肿瘤、多个肿瘤或大血管侵犯的肝细胞癌的一种安全有效的方法。
Medicine (Baltimore). 2015 Jan;94(3):e396. doi: 10.1097/MD.0000000000000396.
4
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.雷莫芦单抗联合紫杉醇对比紫杉醇单药二线治疗晚期胃癌的随机对照、多中心、III 期临床研究
J Clin Oncol. 2015 Jan 10;33(2):172-9. doi: 10.1200/JCO.2013.54.3298. Epub 2014 Dec 8.
5
Epigenetics in liver disease.肝脏疾病中的表观遗传学
Hepatology. 2014 Oct;60(4):1418-25. doi: 10.1002/hep.27131. Epub 2014 May 7.
6
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.舒尼替尼与索拉非尼治疗晚期肝细胞癌的随机对照 III 期临床试验结果。
J Clin Oncol. 2013 Nov 10;31(32):4067-75. doi: 10.1200/JCO.2012.45.8372. Epub 2013 Sep 30.
7
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.Brivanib 对比索拉非尼作为不可切除的晚期肝细胞癌患者的一线治疗：BRISK-FL 研究的随机 III 期结果。
J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26.
8
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.索拉非尼治疗晚期肝细胞癌的 II 期随机剂量递增试验。
Oncologist. 2013;18(4):379-80. doi: 10.1634/theoncologist.2012-0221. Epub 2013 Apr 11.
9
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
10
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.